EIGR
Income statement / Annual
Last year (2023), Eiger BioPharmaceuticals, Inc.'s total revenue was $15.77 M,
an increase of 16.98% from the previous year.
In 2023, Eiger BioPharmaceuticals, Inc.'s net income was -$74.96 M.
See Eiger BioPharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$15.77 M |
$13.48 M |
$12.14 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$24,000.00
|
$1.84 M
|
$745,000.00
|
$645,000.00
|
$486,000.00
|
$54,000.00
|
$41,000.00
|
$23,000.00
|
$11,000.00
|
$0.00
|
| Gross Profit |
$15.75 M
|
$11.65 M
|
$11.40 M
|
-$645,000.00
|
-$486,000.00
|
-$54,000.00
|
-$41,000.00
|
-$23,000.00
|
-$11,000.00
|
$0.00
|
| Gross Profit Ratio |
1
|
0.86
|
0.94
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$62.33 M
|
$75.28 M
|
$64.44 M
|
$41.59 M
|
$51.79 M
|
$37.09 M
|
$29.52 M
|
$33.01 M
|
$21.96 M
|
$22.68 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$20.56 M
|
$17.11 M
|
$13.96 M
|
$12.00 M
|
$13.11 M
|
$12.44 M
|
$10.34 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$25.20 M
|
$29.11 M
|
$23.90 M
|
$20.56 M
|
$17.11 M
|
$13.96 M
|
$12.00 M
|
$13.11 M
|
$12.44 M
|
$10.34 M
|
| Other Expenses |
$0.00
|
-$963,000.00
|
$46.49 M
|
-$12,000.00
|
-$15,000.00
|
-$12,000.00
|
$186,000.00
|
-$277,000.00
|
$5,000.00
|
-$835,000.00
|
| Operating Expenses |
$87.54 M
|
$104.39 M
|
$88.34 M
|
$62.15 M
|
$68.90 M
|
$51.05 M
|
$41.52 M
|
$46.12 M
|
$34.39 M
|
$33.02 M
|
| Cost And Expenses |
$87.56 M
|
$106.22 M
|
$89.08 M
|
$62.15 M
|
$68.90 M
|
$51.05 M
|
$41.52 M
|
$46.12 M
|
$34.39 M
|
$33.02 M
|
| Interest Income |
$2.21 M
|
$1.08 M
|
$158,000.00
|
$704,000.00
|
$2.07 M
|
$997,000.00
|
$410,000.00
|
$0.00
|
$65,000.00
|
$118,000.00
|
| Interest Expense |
$5.47 M
|
$4.13 M
|
$3.56 M
|
$3.59 M
|
$3.41 M
|
$2.33 M
|
$1.52 M
|
$690,000.00
|
$2.30 M
|
$741,000.00
|
| Depreciation & Amortization |
$750,000.00
|
$119,000.00
|
$46.65 M
|
$1.34 M
|
$2.54 M
|
$54,000.00
|
$41,000.00
|
$23,000.00
|
$504,000.00
|
$153,000.00
|
| EBITDA |
-$68.74 M |
-$92.62 M |
-$76.94 M |
-$60.81 M |
-$66.36 M |
-$50.06 M |
-$40.92 M |
-$46.40 M |
-$33.82 M |
-$33.02 M |
| EBITDA Ratio |
-4.36
|
-6.87
|
-2.49
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-4.55
|
-6.88
|
-6.34
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$3.17 M
|
-$4.01 M
|
$43.09 M
|
-$2.90 M
|
-$1.35 M
|
-$1.34 M
|
-$928,000.00
|
-$967,000.00
|
-$2.23 M
|
-$835,000.00
|
| Income Before Tax |
-$74.96 M
|
-$96.75 M
|
-$33.85 M
|
-$65.05 M
|
-$70.25 M
|
-$52.39 M
|
-$42.45 M
|
-$47.09 M
|
-$44.41 M
|
-$33.85 M
|
| Income Before Tax Ratio |
-4.75
|
-7.18
|
-2.79
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$6,000.00
|
$23,000.00
|
$64,000.00
|
$3.58 M
|
$3.39 M
|
$985,000.00
|
$1.67 M
|
$390,000.00
|
$2.31 M
|
-$153,000.00
|
| Net Income |
-$74.96 M
|
-$96.78 M
|
-$33.92 M
|
-$68.63 M
|
-$73.64 M
|
-$52.39 M
|
-$42.45 M
|
-$47.09 M
|
-$44.41 M
|
-$33.85 M
|
| Net Income Ratio |
-4.75
|
-7.18
|
-2.79
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-50.78 |
-69.74 |
-0.98 |
-2.3 |
-3.01 |
-3.84 |
-4.86 |
-5.63 |
-35.11 |
-21.62 |
| EPS Diluted |
-50.78 |
-69.74 |
-0.98 |
-2.3 |
-3.01 |
-3.84 |
-4.86 |
-5.63 |
-35.11 |
-21.62 |
| Weighted Average Shares Out |
$1.48 M
|
$1.39 M
|
$34.63 M
|
$29.88 M
|
$24.43 M
|
$13.63 M
|
$8.73 M
|
$8.36 M
|
$1.27 M
|
$1.57 M
|
| Weighted Average Shares Out Diluted |
$1.48 M
|
$1.39 M
|
$34.63 M
|
$29.88 M
|
$24.50 M
|
$13.63 M
|
$8.73 M
|
$8.36 M
|
$1.27 M
|
$1.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
